国家卫生健康行业标准《儿科输血指南》中血液病患儿输血的编制说明与解读

doi:10.7499/j.issn.1008-8830.2410093

摘要
图/表
参考文献(41)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (592 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要为了指导儿童患者的临床输血实践，国家卫生健康委员会发布了卫生健康行业标准《儿科输血指南》（WS/T 795-2022）。输血是血液病患儿最常用的支持治疗手段之一，该指南对再生障碍性贫血、地中海贫血、自身免疫性溶血性贫血、葡萄糖-6-磷酸脱氢酶缺乏症、急性白血病和骨髓增生异常综合征、免疫性血小板减少症、血栓性血小板减少性紫癜等患儿的输血给出了指导和建议。该文介绍了《儿科输血指南》中血液病患儿输血条款内容的证据与解读，希望对该指南的血液病患儿输血部分的理解和贯彻实施有所助益。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵明一
	黄蓉
	桂嵘
	何庆南
	黑明燕
	竺晓凡
	卢俊
	徐晓军
	袁天明
	张蓉
	王旭
	刘晋萍
	王静
	邵智利
	郭永建
	吴心音
	陈佳睿
	陈琦蓉
	郭佳
	杨明华

关键词 ：再生障碍性贫血, 地中海贫血, 自身免疫性溶血性贫血, 急性白血病, 血小板减少症, 儿童

Abstract：To guide clinical blood transfusion practices for pediatric patients, the National Health Commission has issued the health standard "Guideline for pediatric transfusion" (WS/T 795-2022). Blood transfusion is one of the most commonly used supportive treatments for children with hematological diseases. This guideline provides guidance and recommendations for blood transfusions in children with aplastic anemia, thalassemia, autoimmune hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, acute leukemia, myelodysplastic syndromes, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura. This article presents the evidence and interpretation of the blood transfusion provisions for children with hematological diseases in the "Guideline for pediatric transfusion", aiming to assist in the understanding and implementing the blood transfusion section of this guideline.

Key words： Aplastic anemia Thalassemia Autoimmune hemolytic anemia Acute leukemia Thrombocytopenia Child

收稿日期: 2024-10-23

通讯作者: 杨明华，男，主任医师。Email：yangminghua@csu.edu.cn。 E-mail: yangminghua@csu.edu.cn

作者简介: 赵明一，女，博士，副研究员；黄蓉，女，博士，副主任技师；

引用本文:

赵明一,黄蓉,桂嵘等. 国家卫生健康行业标准《儿科输血指南》中血液病患儿输血的编制说明与解读[J]. 中国当代儿科杂志, 2025, 27(1): 18-25.

ZHAO Ming-Yi,HUANG Rong,GUI Rong et al. Explanation and interpretation of blood transfusion provisions for children with hematological diseases in the national health standard "Guideline for pediatric transfusion"[J]. CJCP, 2025, 27(1): 18-25.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2410093 或 http://www.zgddek.com/CN/Y2025/V27/I1/18

	1 中华人民共和国国家卫生健康委员会法规司. 关于发布《输血相容性检测标准》等3项推荐性卫生行业标准的通告: 国卫通〔2022〕1号[EB/OL]. (2022-02-23)[2022-09-01].
	Case RB, Berglund E, Sarnoff SJ. Ventricular function. VII. Changes in coronary resistance and ventricular function resulting from acutely induced anemia and the effect thereon of coronary stenosis[J]. Am J Med, 1955, 18(3): 397-405. PMID: 14349964. DOI: 10.1016/0002-9343(55)90219-9.
	Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members[J]. JAMA, 2014, 312(10): 1033-1048. PMID: 25203083. DOI: 10.1001/jama.2014.10517.
	New HV, Berryman J, Bolton-Maggs PH, et al. Guidelines on transfusion for fetuses, neonates and older children[J]. Br J Haematol, 2016, 175(5): 784-828. PMID: 27861734. DOI: 10.1111/bjh.14233.
	Sagmeister M, Oec L, Gmür J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia[J]. Blood, 1999, 93(9): 3124-3126. PMID: 10216111.
	Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation[J]. Cochrane Database Syst Rev, 2012(5): CD004269. PMID: 22592695. DOI: 10.1002/14651858.CD004269.pub3.
	Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J]. N Engl J Med, 2013, 368(19): 1771-1780. PMID: 23656642. DOI: 10.1056/NEJMoa1212772.
	Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016, 172(2): 187-207. PMID: 26568159. DOI: 10.1111/bjh.13853.
	9 Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent thalassaemia (NTDT): 2nd edition[EB/OL]. [2021-08-06]. https://thalassaemia.org.cy/wp-content/uploads/2017/10/NTDT-final-combined-1.pdf.
	10 Cappellini MD, Farmakis D, Porter J, et al. 2021 Guidelines for the management of transfusion dependent thalassaemia (TDT): 4th edition[EB/OL]. [2021-08-06]. https://www.thalassemia.org/wp-content/uploads/2021/06/TIF-2021-Guidelines-for-Mgmt-of-TDT.pdf.
	Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of β thalassaemia intermedia[J]. Br J Haematol, 2011, 152(5): 512-523. PMID: 21250971. DOI: 10.1111/j.1365-2141.2010.08486.x.
	Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia[J]. Eur J Intern Med, 2011, 22(6): 607-610. PMID: 22075289. DOI: 10.1016/j.ejim.2011.05.013.
	Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran[J]. Thromb Haemost, 2006, 96(4): 488-491. PMID: 17003927.
	Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study[J]. Blood, 2010, 115(10): 1886-1892. PMID: 20032507. DOI: 10.1182/blood-2009-09-243154.
	Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia[J]. J Thromb Haemost, 2010, 8(1): 54-59. PMID: 19817994. DOI: 10.1111/j.1538-7836.2009.03651.x.
	Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia [J]. Eur Spine J, 2010, 19(6): 871-878. PMID: 20204423. PMCID: PMC2899982. DOI: 10.1007/s00586-010-1357-2.
	Musallam KM, Taher AT, Karimi M, et al. Cerebral infarction in β-thalassemia intermedia: breaking the silence[J]. Thromb Res, 2012, 130(5): 695-702. PMID: 22857801. DOI: 10.1016/j.thromres.2012.07.013.
	Sankaran J, Rodriguez V, Jacob EK, et al. Autoimmune hemolytic anemia in children: mayo clinic experience[J]. J Pediatr Hematol Oncol, 2016, 38(3): e120-e124. PMID: 26925716. DOI: 10.1097/MPH.0000000000000542.
	19 Cohn CS, Delaney M, Johnson ST, et al. Technical Manual[M]. 20th ed. Bethesda: American Association of Blood Banks, 2020.
	Salama A, Bergh?fer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia[J]. Lancet, 1992, 340(8834/8835): 1515-1517. PMID: 1361607. DOI: 10.1016/0140-6736(92)92766-9.
	Ladogana S, Maruzzi M, Samperi P, et al. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association[J]. Blood Transfus, 2017, 15(3): 259-267. PMID: 28151390. PMCID: PMC5448833. DOI: 10.2450/2016.0072-16.
	Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue[J]. J Clin Apher, 2019, 34(3): 171-354. PMID: 31180581. DOI: 10.1002/jca.21705.
	中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组, 中国医师协会医学遗传医师分会临床生化遗传专业委员会, 中国医师协会青春期医学专业委员会临床遗传学组. 葡萄糖-6-磷酸脱氢酶缺乏症新生儿筛查、诊断和治疗专家共识[J]. 中华儿科杂志, 2017, 55(6): 411-414. PMID: 28592006. DOI: 10.3760/cma.j.issn.0578-1310.2017.06.003.
	24 杨雪, 谭春泽, 李聚林. 葡萄糖-6-磷酸脱氢酶缺乏症急性溶血与安全输血最新研究进展[J]. 中国实验血液学杂志, 2018, 26(5): 1569-1573. DOI: 10.7534/j.issn.1009-2137.2018.05.052.
	Estcourt LJ, Stanworth SJ, Doree C, et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev, 2015, 2015(11): CD010983. PMID: 26576687. PMCID: PMC4717525. DOI: 10.1002/14651858.CD010983.pub2.
	Schiffer CA, Bohlke K, Anderson KC. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update summary[J]. J Oncol Pract, 2018, 14(2): 129-133. PMID: 29182492. DOI: 10.1200/JOP.2017.028902.
	Kumar A, Mhaskar R, Grossman BJ, et al. Platelet transfusion: a systematic review of the clinical evidence[J]. Transfusion, 2015, 55(5): 1116-1127. PMID: 25387589. DOI: 10.1111/trf.12943.
	Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB[J]. Ann Intern Med, 2015, 162(3): 205-213. PMID: 25383671. DOI: 10.7326/M14-1589.
	29 The C17Guidelines Committee. Guideline for platelet transfusion thresholds for pediatric hematology/oncology patients[M]. [2021-08-06]. https://c17.ca/application/files/6916/2006/0819/C17_Platelet_Guideline_English_Complete_2011.pdf.
	D'Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology and current treatment approaches[J]. J Pediatr Hematol Oncol, 2013, 35(1): 1-13. PMID: 23073045. DOI: 10.1097/MPH.0b013e318271f457.
	Peng J, Friese P, Heilmann E, et al. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression[J]. Blood, 1994, 83(1): 161-166. PMID: 7506077.
	Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood, 2010, 115(2): 168-186. PMID: 19846889. DOI: 10.1182/blood-2009-06-225565.
	中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）[J]. 中华血液学杂志, 2020, 41(8): 617-623. PMID: 32942813. PMCID: PMC7525165. DOI: 10.3760/cma.j.issn.0253-2727.2020.08.001.
	Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions[J]. Br J Haematol, 2017, 176(3): 365-394. PMID: 28009056. DOI: 10.1111/bjh.14423.
	Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients[J]. Am J Hematol, 2008, 83(2): 122-125. PMID: 17874448. DOI: 10.1002/ajh.21060.
	Siddiqui A, Journeycake JM, Borogovac A, et al. Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children[J]. Pediatr Blood Cancer, 2021, 68(5): e28949. PMID: 33660913. DOI: 10.1002/pbc.28949.
	Lara PN, Coe TL, Zhou H, et al. Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome[J]. Am J Med, 1999, 107(6): 573-579. PMID: 10625026. DOI: 10.1016/s0002-9343(99)00286-7.
	中华医学会血液学分会血栓与止血学组. 血栓性血小板减少性紫癜诊断与治疗中国指南（2022年版）[J]. 中华血液学杂志, 2022, 43(1): 7-12. PMID: 35231985. PMCID: PMC8980665. DOI: 10.3760/cma.j.issn.0253-2727.2022.01.002.
	Coppo P, Bussel A, Charrier S, et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome[J]. Medicine (Baltimore), 2003, 82(1): 27-38. PMID: 12544708. DOI: 10.1097/00005792-200301000-00003.
	Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality[J]. Blood, 2015, 125(9): 1470-1476. PMID: 25588677. PMCID: PMC4342358. DOI: 10.1182/blood-2014-10-605493.
	Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition[J]. Haemophilia, 2020, 26Suppl 6: 1-158. PMID: 32744769. DOI: 10.1111/hae.14046.